For the Week of February 8, 2016

Were there any new technology add-on payments listed in the inpatient PPS that took effect on October 1, 2015? 

The inpatient prospective payment system (IPPS) final rule authorized a new technology add-on payment for bilatumonmab, which was approved by the Food & Drug Administration (FDA) December, 2014, for the treatment of a form of B-cell acute lymphoblastic leukemia. The maximum add-on payment for the drug during fiscal year (FY) 2016 is $27,017.85 per case.